Sacral neuromodulation: Therapy evolution

Indian Journal of Urology

Volumn 26, Issue 3, 2010, Pages 379-384

  Thompson, Jannah H ^a   Sutherland, Suzette E ^a   Siegel, Steven W ^a  

^a Metropolitan Urology   (United States)

Author keywords

neuromodulation; non obstructive; Refractory overactive

Indexed keywords

BOTULINUM TOXIN; CHOLINERGIC RECEPTOR BLOCKING AGENT; PLACEBO;

BILATERAL PERCUTANEOUS NERVE EVALUATION; CONFERENCE PAPER; CONSTIPATION; COST; DEVICE; FECES INCONTINENCE; FLUOROSCOPY; FOOD AND DRUG ADMINISTRATION; HUMAN; INTERSTITIAL CYSTITIS; LOCAL ANESTHESIA; MICTURITION REFLEX; NERVE STIMULATION; NEUROGENIC BLADDER; NEUROMODULATION; OVERACTIVE BLADDER; PELVIS PAIN SYNDROME; POSITRON EMISSION TOMOGRAPHY; PUDENDAL NERVE; PULSE GENERATOR; QUALITY OF LIFE; SACRAL NEUROMODULATION; SACRAL PLEXUS; SEDATION; SPINAL ROOT; TINED LEAD; TREATMENT INDICATION; URINE RETENTION;

EID: 77957915277     PISSN: 09701591     EISSN: 19983824     Source Type: Journal    
DOI: 10.4103/0970-1591.70576     Document Type: Conference Paper

References (26)

1. rd ed. Ch. 22. Philadelphia: WB Saunders Company; 2008. p. 266-76.
2. Abrams P, Blavais JG, Fowler CJ, Fourcroy JL, Macdiarmid SA, Siegel SW, et al. The role of neuromodulation in the management of urinary urge incontinence. BJU Int 2002;91:335-9.
3. Diokno AC, Appell RA, Sand PK, Dmochowski RR, Gburek BM, Klimberg IW, et al. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc 2003;78:687-95.
4. Schmidt RA, Bruschini H, Tanagho EA. Sacral root stimulation in controlled micturition. Peripheral somatic neuroanatomy and stimulated voiding. Invest Urol 1979;17:130-4.
5. Tanagho EA, Schmidt RA. Electrical stimulation in the clinical management of the neurogenic bladder. J Urol 1988;140:1331.
6. rd ed. Philadelphia, PA: WB Saunders Company; 2008. p. 26-46.
7. TM Therapy for sacral neuromodulation: impact on treatment success and safety. Eur Urol 2008;54:1287-96.
8. DasGupta R, Critchley HD, Dolan RJ, Fowler CJ. Changes in brain activity following sacral neuromodulation for urinary retention. J Urol 2005;174:2268-72.
9. Sutherland SE, Siegel SW. Sacral nerve stimulation for overactive bladder symptoms. In: Kreder K, Dmochowski R, editors. The Overactive Bladder Evaluation and Management. Ch 26. London: Informa Health Care; 2007. p. 303-18.
10. van Kerrebroeck PE, van Voskuilen AC, Heesakkers JP, Lycklama á Nijholt AA, Siegel S, Jonas U, et al. Results of sacral neuromodulation therapy for urinary voiding dysfunction: outcomes of a prospective, worldwide clinical study. J Urol 2007;178:2029-34.
11. Sutherland SE, Lavers A, Carlson A, Holtz C, Kesha J, Siegel SW. Sacral nerve stimulation for voiding dysfunction: One institution's 11 year experience. Neurourol Urodyn 2007;26:19-28.
12. Spinelli M, Giardiello G, Gerber M, Arduini A, van den Hombergh U, Malaguti S. New sacral neuromodulation lead for percutaneous implantation using local anesthesia: description and first experience. J Urol 2003;170:1905-7.
13. Janknegt RA, Weil EH, Eerdmans PH. Improving neuromodulation technique for refractory voiding dysfunctions: two stage implant. Urology 1997;49:358-62.
14. Bernstein AJ, Peters KM. Expanding indications for neuromodulation. Urol Clinics N Am 2005;32:59-63.
15. Paszkiewicz EJ, Siegel SW, Kirkpatrick C, Hinkel B, Kesha J, Kirkemo A. Sacral nerve stimulation in patients with chronic, intractable pelvic pain. Urology 2001;57:124.
16. Altomare DF, Ratto C, Ganio E, Lolli P, Masin A, Villani R. Long term outcome of sacral nerve stimulation for fecal incontinence. Dis Colon Rectum 2009;52:11-7.
17. Roth TJ, Vandersteen DR, Hollatz P, Inman BA, Reinberg YE. Sacral neuromodulation for the dysfunctional elimination syndrome: a single center experience with 20 children. J Urol 2008;180:306-11.
18. Peters KM, Feber KM, Bennett RC. Sacral versus pudendal nerve stimulation for voiding dysfunction: a prospective, single-blinded, randomized, crossover trial. Neurourol Urodyn 2005;24:643-7.
19. Hu TW, Wagner TH, Bentkover JD, Leblanc K, Zhou SZ, Hunt T Costs of urinary incontinence and overactive bladder in the united states: a comparative study. Urology 2004;63:461-5.
20. Hay-Smith J, Herbison P, Ellis G, Morris A. Which Anticholinergic Drug for Overactive Bladder Symptoms in Adults. Cochrane Database Syst Rev 2005;3:CD005429.
21. Aboseif SR, Kim DH, Rieder JM, Rhee EY, Menefee SA, Kaswick JR, Ree MH. sacral neuromodulation: cost considerations and clinical benefits. Urology 2007;70:1069-73.
22. Montecucco C, Schiavo G, Tugnoli V, de Grandis D. Botulinum neurotoxins: mechanisms of action and therapeutic applications. Mol Med Today 1996;2:418-24.
23. Duthie J, Wilson DI, Herbison GP, Wilson D. Botulinum toxin injections for adults with overactive bladder syndrome. Cochrane Database Syst Rev 2007;3:CD005493.
24. Sahai A, Dowson C, Khan MS, Dasgupta P. Improvement in quality of life after botulinum toxin-a injections for idiopathic detrusor overactivity: results from a randomized double-blind placebo-controlled trial. BJU Int 2009;103:1509-15.
25. Kalsi V, Popat RB, Apostolidis A, Kavia R, Odeyemi IA, Dakin HA, et al. Cost-Consequence Analysis Evaluating the Use of Botulinum Neurotoxin-A in Patients with Detrusor Overactivity Based on Clinical Outcomes Observed at a Single UK Centre. Eur Urol 2006;49:519-27.
26. Glinski RW, Siegel S. Refractory overactive bladder: beyond oral anticholinergic therapy. Indian J Urol 2007;23:166-73.